Last reviewed · How we verify
Hyperpolarized 13C-Urea
At a glance
| Generic name | Hyperpolarized 13C-Urea |
|---|---|
| Also known as | HP13C-urea, copol |
| Sponsor | Michael Ohliger, MD PhD |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- Hyperpolarized 13C Pyruvate MRI Scan in Predicting Tumor Aggressiveness in Patients With Renal Tumors (PHASE2)
- Magnetic Resonance (MR) Imaging With Hyperpolarized 13C-Pyruvate +/- 13C,15N-Urea in Patients With Prostate Cancer (PHASE2)
- Hyperpolarized 13C MRI as a Biomarker in Advanced Solid Tumors (PHASE1, PHASE2)
- Pilot Study of (MR) Imaging with Pyruvate (13C) to Detect High Grade Prostate Cancer (EARLY_PHASE1)
- Hyperpolarized Pyruvate (13C) Magnetic Resonance Imaging In Patients With Fatty Liver Disease
- Study to Evaluate the Feasibility of 13-C Pyruvate Imaging in Breast Cancer Patients Receiving Neoadjuvant Chemotherapy (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Hyperpolarized 13C-Urea CI brief — competitive landscape report
- Hyperpolarized 13C-Urea updates RSS · CI watch RSS
- Michael Ohliger, MD PhD portfolio CI